Justin Waite on X: ""Upon FDA approval (90% probability), we value Polarean #POLX at 135p per share on a risk-adjusted NPV basis, which implies c.50% upside to the current share price, hence
Polarean Imaging's (LON:POLX) investors will be pleased with their notable 96% return over the last three years
Questor: long Covid breathes yet more life into this maker of MRI image enhancers